A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin is engineering several ways to compete in its next generation.
The agency combed trials, real-world claims data, and case reports for two years before putting NAION on every GLP-1 label. The absolute risk is tiny, the relative signal is real, and the decision says a lot about how FDA weighs incomplete evidence.
The FDA approved Bayer's asundexian, the first factor XIa inhibitor ever, cutting ischemic stroke risk by 26% on top of antiplatelet therapy with similar overall major bleeding. The class that failed in atrial fibrillation now enters the market as a stroke-recurrence drug.